\r\n\r\nASH Abstract: 640: Davids MS, Brander DM, Tyekucheva S, et al. Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia.\r\n\r\n \r\n\r\nhttps:\/\/ash.confex.com\/ash\/2021\/webprogram\/Paper146624.html\r\n\r\n"}}}; dataLayer.push( dataLayer_content );

Skip to Content

desember 2021

Long-term remission found with combination therapy for young patients with CLL

A 2.5-year time-limited regimen with combination treatment of ibrutinib and FCR shows potential to generate long-term remission for a group of young patients with chronic lymphocytic leukemia.